非诺贝特纳米混悬剂的生物利用度研究  

Preparation and bioavailability evaluation of fenofibrate nanosuspension

作　　者：罗宁[1,1,2] 胡富强[1] 袁弘[1] 

机构地区：[1]浙江大学药学院,浙江杭州310027 [2]浙江医药高等专科学校

出　　处：《吉林医学》2011年第19期3849-3851,共3页Jilin Medical Journal

摘　　要：目的:制备非诺贝特纳米混悬剂胶囊,分别在空腹和饱腹条件下,有大鼠灌胃非诺贝特纳纳米混悬剂,考察其体内吸收特性,并与市售微粉化非诺贝特胶囊进行对照,评价其相对生物利用度。方法:以高效液相色谱法测定大鼠灌胃给药前后的血药浓度。结果:与市售微粉化胶囊相比,在饱腹和空腹条件下,非诺贝特纳米混悬剂胶囊相对生物利用度分别达到136.45%和148.48%。结论:非诺贝特纳米混悬剂胶囊与市售微粉化胶囊相比,生物利用度较高。Objective Fenofribate nanosuspension capsule was prepared.Fasted and fed rats were intragastrical administrate nanosuspension,respectively,studying the in vivo absorption and comparing commercially micronized fenofribate capsules,evaluated the relative bioavailability.Method The plasma concentrations in rats were measured by HPLC.Results In satiety and fasting conditions,the relative bioavailability has reached to 136.45% and 148.48% compared with the commercial capsule.Conclusion The bioavailability of fenofribate nanosuspension capsule enhances compared with the commercially micronized.

关 键 词：非诺贝特 纳米粒 纳米混悬剂 生物利用度 

分 类 号：R944[医药卫生—药剂学]